Menu
Search
|

Menu

Close
X

Axsome Therapeutics Inc AXSM.OQ (NASDAQ Stock Exchange Global Market)

15.01 USD
+0.11 (+0.74%)
As of Apr 18
Previous Close 14.90
Open 14.99
Volume 239,267
3m Avg Volume 433,017
Today’s High 15.38
Today’s Low 14.34
52 Week High 16.80
52 Week Low 1.94
Shares Outstanding (mil) 23.61
Market Capitalization (mil) 146.39
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.40 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-1.145
FY17
-1.288
FY16
-1.420
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.55
Price to Sales (TTM)
vs sector
--
8.39
Price to Book (MRQ)
vs sector
6.43
5.27
Price to Cash Flow (TTM)
vs sector
--
24.13
Total Debt to Equity (MRQ)
vs sector
43.83
16.01
LT Debt to Equity (MRQ)
vs sector
35.50
11.32
Return on Investment (TTM)
vs sector
-90.07
13.83
Return on Equity (TTM)
vs sector
-102.68
15.25

EXECUTIVE LEADERSHIP

Herriot Tabuteau
Chairman of the Board, President, Chief Executive Officer, Since 2018
Salary: $435,000.00
Bonus: --
Nick Pizzie
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Joseph Debrah-Affu
Director of Finance, Interim Principal Accounting Officer, Since 2018
Salary: --
Bonus: --
Mark Jacobson
Senior Vice President- Operations, Secretary, Since 2017
Salary: --
Bonus: --
Cedric O'Gorman
Senior Vice President- Clinical Development and Medical Affairs, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

25 Broadway Fl 9
NEW YORK   NY   10004-1058

Phone: +1212.3323241
Site: axsome.com/

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).

SPONSORED STORIES